• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Insmed Incorporated

    9/3/24 5:22:55 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INSM alert in real time by email
    SC 13G 1 p24-2682sc13g.htm

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
    (Amendment No. __)*
     

    Insmed Incorporated

    (Name of Issuer)
     

    Common stock, par value $0.01 per share

    (Title of Class of Securities)
     

    457669307

    (CUSIP Number)
     

    August 23, 2024

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    þ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 8 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 45766930713GPage 2 of 8 Pages

     

    1

    NAME OF REPORTING PERSON

    Darwin Global Management, Ltd.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) o

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Jersey

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    9,717,822 shares of Common Stock

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    9,717,822 shares of Common Stock

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    9,717,822 shares of Common Stock

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.7%

    12

    TYPE OF REPORTING PERSON

    IA, OO

             

     

     

     

     

    CUSIP No. 45766930713GPage 3 of 8 Pages

     

    1

    NAME OF REPORTING PERSON

    Dr. Abhishek Trehan

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) o

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United Kingdom

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    9,717,822 shares of Common Stock

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    9,717,822 shares of Common Stock

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    9,717,822 shares of Common Stock

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.7%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

     

    CUSIP No. 45766930713GPage 4 of 8 Pages

     

    1

    NAME OF REPORTING PERSON

    Darwin Global Master Fund, Ltd.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) o

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    9,314,373 shares of Common Stock

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    9,314,373 shares of Common Stock

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    9,314,373 shares of Common Stock

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.4%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

     

     

     

    CUSIP No. 45766930713GPage 5 of 8 Pages

     

    Item 1(a). NAME OF ISSUER
       
      Insmed Incorporated (the “Issuer”).

     

    Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES
       
      700 US Highway 202/206, Bridgewater, New Jersey 08807.

     

    Item 2(a). NAME OF PERSON FILING
       
     

    This statement is filed by:

     

    (i) Darwin Global Management, Ltd., a limited company incorporated under the laws of Jersey (“Darwin Global”). The shares of Common Stock (as defined in Item 2(d) below) to which this filing relates are held directly by (a) Master Fund (as defined below), to which Darwin Global serves as investment manager and (b) a segregated account (the “Segregated Account”) for which Darwin Global serves as an appointed sub-investment advisor;

     

    (ii) Dr. Abhishek Trehan (“Dr. Trehan”), the Chief Investment Officer and the controlling person of Darwin Global, with respect to the shares of Common Stock held by each of Master Fund and the Segregated Account; and

     

    (iii) Darwin Global Master Fund Ltd. (“Master Fund”), a Cayman Islands exempted company, with respect to the shares of Common Stock held by it.

     

    The foregoing persons are hereinafter sometimes each referred to as a “Reporting Person” and collectively referred to as the “Reporting Persons.”

     

    The filing of this statement should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
       
      The address of the business office of each of the Reporting Persons is Whiteley Chambers, Don Street, St. Helier, Jersey JE2 4TR.

     

    Item 2(c). CITIZENSHIP
       
      Darwin Global is a Jersey limited company. Dr. Trehan is a British citizen. Master Fund is a Cayman Islands exempted company.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
       
      Common stock, par value $0.01 per share (the "Common Stock").

     

    Item 2(e). CUSIP NUMBER
       
      457669307

     

     

    CUSIP No. 45766930713GPage 6 of 8 Pages

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) o An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

      (g) o

    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution: ______________________________________

     

    Item 4. OWNERSHIP
       
     

    The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page and is incorporated herein by reference.

     

    The percentage set forth in Row 11 of this Schedule 13G is calculated based upon 171,849,103 shares of Common Stock outstanding as of August 2, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the Securities and Exchange Commission on August 8, 2024.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
       
      Not applicable.

     

     

    CUSIP No. 45766930713GPage 7 of 8 Pages

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
       
      See Item 2.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
       
      Not applicable.

     

    Item 10. CERTIFICATION

     

      Each Reporting Person hereby makes the following certification:
       
      By signing below, each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
       

     

     

    CUSIP No. 45766930713GPage 8 of 8 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: September 3, 2024

     

    DARWIN GLOBAL MANAGEMENT, LTD.  
       
    /s/ John Legge  
    Name: John Legge  
    Title: Director and Chief Financial Officer  
       
       
     /s/ Dr. Abhishek Trehan  
    DR. ABHISHEK TREHAN  

     

     

     
    DARWIN GLOBAL Master fund, LTD.  

     

    By: DARWIN GLOBAL MANAGEMENT, LTD, its investment manager

     
       
    /s/ John Legge  
    Name: John Legge  
    Title: Director and Chief Financial Officer  

     

     

     

     

    Get the next $INSM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $INSM

    DatePrice TargetRatingAnalyst
    5/13/2025$105.00Buy
    Jefferies
    2/25/2025$100.00Outperform
    RBC Capital Mkts
    4/23/2024$48.00Buy
    Truist
    2/15/2024$42.00Outperform
    Wolfe Research
    12/8/2023$55.00Overweight
    Wells Fargo
    11/20/2023$36.00Overweight
    JP Morgan
    7/26/2023$50.00Buy
    Guggenheim
    12/9/2022$28.00Buy
    Mizuho
    More analyst ratings

    $INSM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on Insmed with a new price target

      Jefferies initiated coverage of Insmed with a rating of Buy and set a new price target of $105.00

      5/13/25 9:43:52 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Insmed with a new price target

      RBC Capital Mkts initiated coverage of Insmed with a rating of Outperform and set a new price target of $100.00

      2/25/25 7:09:15 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Truist initiated coverage on Insmed with a new price target

      Truist initiated coverage of Insmed with a rating of Buy and set a new price target of $48.00

      4/23/24 6:29:24 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INSM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Insmed Announces Pricing of $750 Million Public Offering of Common Stock

      BRIDGEWATER, N.J., June 11, 2025 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it priced an underwritten public offering of 7,812,500 shares of its common stock at a price to the public of $96.00 per share. The gross proceeds to Insmed from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Insmed, are expected to be approximately $750 million. In addition, Insmed has granted the underwriters a 30-day option to purchase up to an additional 1,171,875

      6/11/25 10:25:00 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Insmed Announces Proposed $650 Million Public Offering of Common Stock

      BRIDGEWATER, N.J., June 11, 2025 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it intends to offer and sell $650 million of shares of its common stock in an underwritten public offering. In addition, Insmed intends to grant the underwriters a 30-day option to purchase up to an additional $97.5 million of shares of common stock. All of the shares to be sold in the offering are to be sold by Insmed. The offering is subject to market and other conditions, and there can be no assurance as to whether or when th

      6/11/25 4:01:00 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension

      –The Study Met Primary and All Secondary Efficacy Endpoints– Statistically Significant 35% Placebo-Adjusted Reduction from Baseline in Pulmonary Vascular Resistance for the Primary Endpoint (p<0.001) 35.5 Meter Placebo-Adjusted Improvement in Six-Minute Walk Distance for the Secondary Efficacy Endpoint (p=0.003) 60% Placebo-Adjusted Reduction from Baseline in NT-proBNP Concentrations for the Secondary Efficacy Endpoint (p<0.001) Results Were Assessed Approximately 24 Hours After Administration, Demonstrating Sustained Benefit Throughout the 24-Hour Dosing Period–TPIP Was Well Tolerated in the Study, with 75% of Patients Titrating to the Highest Dose– –Insmed to Immediately Engage with FDA t

      6/10/25 7:00:00 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INSM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for ARIKAYCE KIT issued to INSMED INC

      Submission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-13) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 06/01/2023. Application Category: NDA, Application Number: 207356, Application Classification: Labeling

      6/2/23 4:38:39 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for ARIKAYCE KIT issued to INSMED INC

      Submission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-12) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 02/10/2023. Application Category: NDA, Application Number: 207356, Application Classification: Labeling

      2/13/23 4:39:32 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chair and CEO Lewis William exercised 6,830 shares at a strike of $10.85 and sold $671,612 worth of shares (6,830 units at $98.33) (SEC Form 4)

      4 - INSMED Inc (0001104506) (Issuer)

      7/2/25 4:06:05 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Bonstein Sara exercised 47,889 shares at a strike of $19.16 and sold $5,879,089 worth of shares (57,765 units at $101.78), decreasing direct ownership by 10% to 93,536 units (SEC Form 4)

      4 - INSMED Inc (0001104506) (Issuer)

      6/25/25 4:18:35 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chair and CEO Lewis William sold $13,553,744 worth of shares (135,009 units at $100.39) and exercised 129,805 shares at a strike of $10.85, decreasing direct ownership by 2% to 303,554 units (SEC Form 4)

      4 - INSMED Inc (0001104506) (Issuer)

      6/18/25 4:16:57 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INSM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Desjardins Clarissa bought $201,694 worth of shares (3,025 units at $66.68) (SEC Form 4)

      4 - INSMED Inc (0001104506) (Issuer)

      5/22/25 5:20:35 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INSM
    SEC Filings

    See more
    • SEC Form 144 filed by Insmed Incorporated

      144 - INSMED Inc (0001104506) (Subject)

      6/16/25 5:01:19 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Insmed Incorporated

      144 - INSMED Inc (0001104506) (Subject)

      6/16/25 4:08:41 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Insmed Incorporated filed SEC Form 8-K: Other Events, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - INSMED Inc (0001104506) (Filer)

      6/13/25 8:21:11 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INSM
    Leadership Updates

    Live Leadership Updates

    See more
    • Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List

      —Insmed Leads Science Top Employers List for Fourth Year in a Row— BRIDGEWATER, N.J., Oct. 24, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it has earned the highest ranking in Science's 2024 Top Employers Survey. The annual survey polls employees in biotechnology, pharmaceutical, and related industries to determine the 20 best employers, as well as their driving characteristics. "It is a tremendous honor to have been named the No. 1 employer in Science's annual survey for the fourth consecutive year

      10/24/24 4:05:00 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Insmed Names Drayton Wise Chief Commercial Officer

      BRIDGEWATER, N.J., May 23, 2022 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the appointment of Drayton Wise as Chief Commercial Officer, effective May 23, 2022. In addition to his current responsibilities leading the global ARIKAYCE® (amikacin liposome inhalation suspension) franchise and U.S. commercial activities, Mr. Wise will assume responsibility for all of Insmed's global commercial functions. Mr. Wise will also serve as a member of Insmed's Executive Committee. "We are thrilled to promote Drayton to Chief Commercial Officer at this critical inflecti

      5/23/22 8:00:00 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INSM
    Financials

    Live finance-specific insights

    See more
    • Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension

      –The Study Met Primary and All Secondary Efficacy Endpoints– Statistically Significant 35% Placebo-Adjusted Reduction from Baseline in Pulmonary Vascular Resistance for the Primary Endpoint (p<0.001) 35.5 Meter Placebo-Adjusted Improvement in Six-Minute Walk Distance for the Secondary Efficacy Endpoint (p=0.003) 60% Placebo-Adjusted Reduction from Baseline in NT-proBNP Concentrations for the Secondary Efficacy Endpoint (p<0.001) Results Were Assessed Approximately 24 Hours After Administration, Demonstrating Sustained Benefit Throughout the 24-Hour Dosing Period–TPIP Was Well Tolerated in the Study, with 75% of Patients Titrating to the Highest Dose– –Insmed to Immediately Engage with FDA t

      6/10/25 7:00:00 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update

      —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $92.8 Million for the First Quarter of 2025, Reflecting 23% Growth Over the First Quarter of 2024— —NDA for Brensocatib in Patients with Bronchiectasis Remains on Track, with a PDUFA Target Action Date of August 12, 2025— —Phase 2b Study of TPIP in Patients with PAH Completed; Topline Data Expected in June 2025— —Enrollment Completed for Phase 2b BiRCh Study of Brensocatib in Patients with CRSsNP; Topline Data Anticipated By the End of 2025— —MAA Filings for Brensocatib in Patients with Bronchiectasis Accepted by EMA and MHRA— —Company Reiterates 2025 Global ARIKAYCE Revenue Guidance Range of $405 Million to $425 Million,

      5/8/25 7:00:00 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025

      BRIDGEWATER, N.J., April 23, 2025 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its first-quarter 2025 financial results on Thursday, May 8, 2025. Insmed management will host a conference call for investors beginning at 8:00 a.m. ET on Thursday, May 8, 2025, to discuss financial results and provide a business update. Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (U.S.) and (646) 960-0278 (international) and referencing access code

      4/23/25 7:00:00 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Insmed Incorporated

      SC 13G/A - INSMED Inc (0001104506) (Subject)

      11/14/24 1:22:37 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Insmed Incorporated

      SC 13G - INSMED Inc (0001104506) (Subject)

      9/3/24 5:22:55 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Insmed Incorporated (Amendment)

      SC 13G/A - INSMED Inc (0001104506) (Subject)

      2/16/24 5:43:57 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care